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VDRmThe involvement of calcium-mediated signaling pathways in themechanismof action of 1α,25-dihydroxyvitamin
D3 (1,25D) is currently demonstrated. In this studywe found that 1,25D induces nongenomic effects mediated by
membrane vitamin D receptor (VDRm) by modulating intermediate ﬁlament (IF) phosphorylation and calcium
uptake through L-type voltage-dependent calcium channels (L-VDCC) in cerebral cortex of 10 day-old rats. Re-
sults showed that the mechanism of action of 1,25D involves intra- and extracellular calcium levels, as well as
the modulation of chloride and potassium channels. The effects of L-VDCCs on membrane voltage occur over a
broad potential range and could involve depolarizing or hyperpolarizing coupling modes, supporting a
cross-talk among Ca2+ uptake and potassium and chloride channels. Also, the Na+/K+-ATPase inactivation by
ouabain mimicked the 1,25D action on 45Ca2+ uptake. The Na+/K+-ATPase inhibition observed herein might
lead to intracellular Na+ accumulation with subsequent L-VDCC opening and consequently increased 45Ca2+
(calcium, isotope of mass 45) uptake. Moreover, the 1,25D effect is dependent on the activation of the following
protein kinases: cAMP‐dependent protein kinase (PKA), Ca2+/calmodulin‐dependent protein kinase (PKCaMII),
phosphatidylinositol 3‐kinase (PI3K) and mitogen‐activated protein kinase p38 (p38MAPK). The modulation of
calcium entry into neural cells by the 1,25D we are highlighting, might take a role in the regulation of a plethora
of intracellular processes. Considering that vitamin D deﬁciency can lead to brain illness, 1,25Dmay be a possible
candidate to be used, at least as an adjuvant, in the pharmacological therapy of neuropathological conditions.
© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
1α,25-Dihydroxyvitamin D3 (1,25D), the bioactive metabolite of
vitamin D3, plays an essential role in the regulation of calcium and
bone homeostasis [1]. In addition to these classic functions, vitamin
D3 has been shown to inﬂuence a variety of other systems such as
mammary glands, reproductive organs, osteoblasts and the nervous
system [2–9]. The effects of 1,25D are mediated by its interaction
with a nuclear vitamin D receptor (VDRn), a member of the nuclear
receptor superfamily of ligand-activated transcription factors [10].
This interaction leads to either upregulation or downregulation ofa, Centro de Ciências Biológicas,
o Trindade, CEP: 88040‐970,
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vier OA license. gene expression. On the other hand, it has been reported that 1,25D
acts also through a plasma membrane-associated receptor (VDRm)
which modulates a complex signaling system involving rapid for-
mation of second messengers (Ca2+, cyclic AMP, inositol), activation
of protein kinases (cAMP-dependent protein kinase—PKA; mitogen-
activated protein kinase—MAPK) and the rapid opening of Ca2+ and
Cl− channels [6,7,11–14]. The VDRm has been shown to be localized
in caveolae-enriched plasma membranes [15,16]. However, there is
a current debate on the identity of the receptor(s) involved in
the rapid nongenomic effect of vitamin D. There are two main candi-
dates for the membrane receptor for 1,25D: the MARRS (membrane
associated, rapid response, steroid-binding) protein and also new ev-
idence indicates that the VDRn could also act as a membrane receptor
[17–20].
The VDR is widely distributed in the brain, including neurons and
glial cells and is associated to many different functions [21,22]. Previ-
ous studies have demonstrated that the VDR is expressed in both de-
veloping [23] and adult rat brain [24,25], as well as in human brain
1709L. Zanatta et al. / Biochimica et Biophysica Acta 1823 (2012) 1708–1719[26,27]. Regarding its functions, several studies have postulated that
1,25D modulates the activity of brain genes and enzymes of neuro-
transmitter metabolism, and is also involved in neuroprotection and
brain development [3,4,28,29].
The cytoskeleton of the neural cells comprises a protein network
composed by microtubules, microﬁlaments and intermediate ﬁla-
ments (IFs). Neuroﬁlaments are heteropolymers that are expressed
almost exclusively in neurons. They are composed of three different
polypeptides commonly referred to as heavy (NFH), medium (NFM),
and light (NFL) NF subunits [30]. Under normal conditions, the three
NF subunits coassemble stoichiometrically into ﬁlamentous structures
playing a role in maintaining axonal caliber [31] and axonal transport
[32]. Vimentin and glial ﬁbrillary acidic protein (GFAP) are the IFs
found in astrocytes [30,33]. GFAP is the IF of mature astrocytes [34],
while vimentin is the IF of mesenchymal origin. The phosphorylation
of IF proteins is a dynamic process controlling their physiological role
in response to extracellular signals. The importance of GFAP and NF
subunits on neural function is evident from the fact that perturbation
of their structure accounts for several genetically determined protein
misfolding/aggregation diseases [35]. Also, perikaryal accumulations/
aggregations of NF proteins have been correlated with aberrantly
phosphorylated NF in several neurodegenerative diseases, such as
Alzheimer's disease, motor neuron diseases, and Parkinson's disease
[36–38]. Also, the misregulation of the IF-associated phosphorylation
system is assumed to have an important role in neurodegeneration.
Our research group has previously demonstrated that the phos-
phorylating system associated with the IF proteins is responsive to
hormonal signals [5,39–43]. These actions can be initiated by the
activation of L-type voltage-dependent Ca2+ channels (L-VDCC) and
the signal is transduced downstream of Ca2+ uploading through dif-
ferent kinase pathways, regulating the dynamics of the cytoskeleton
[5,41]. The phosphorylating system associated with the IF proteins
has been previously shown to be targeted by 1,25D in the male repro-
ductive system. However, the intracellular pathways involved in
1,25D actions targeting the neural cytoskeleton and the involvement
of Ca2+ in such actions remain to be identiﬁed.
Calcium signaling plays a central role in neuronal cell develop-
ment. Accordingly, the VDCCs are highly expressed during develop-
ment and their functions are critical for developing neurons [44], as
well as for synaptogenesis [45,46]. One of the ways in which Ca2+
channels inﬂuence neuronal activities is via signaling pathways that
control gene expression and that involve transcription factors such
as cyclic AMP response element-binding protein (CREB) [47,48].
Also, the critical role of VDCCs regulating the secretion of neurotrans-
mitters must be considered [49].
It has been shown that the steroid hormone 1,25D has modulatory
effects on cytoskeleton, neurotransmission, antioxidant system, as well
as Ca2+ and Cl− channel activities in a variety of cell types [5,50–52].
Taking into account these ﬁndings in the present study we explore the
mechanisms involved in the rapid effect of 1,25D on IF phosphorylation
and on 45Ca2+ uptake in slices of cerebral cortex from immature male
rats in an attempt to better understand the relevance of this hormone
to the brain function.
2. Materials and methods
2.1. Chemicals
1α,25-Dihydroxyvitamin D3 (1,25D), nifedipine, 1,2-bis(2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl
ester) (BAPTA-AM), N-[2-(p-bromocinnamylamino) ethyl]-5-
isoquinolinesulfonamide (H89), (bisindoylmaleimidine IX, 2-{1-[3-
(amidinothio)propyl]-1H-indol-3-yl}-3-(1-methylindol-3-yl)maleimide
methanesulfonate salt) Ro 31–8220, (trans-1-(4-hydroxycyclohexyl)-
4-(4-ﬂuorophenyl)-5-(2-methoxypyridimidin-4-yl) imidazole) SB
239063,(2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)PD 98059, ouabain, theophylline, dibutyryl cAMP (di-BucAMP),
9-anthracene carboxylic acid (9-AC), ﬂunarizine, dantrolene sodium
salt, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS), tolbuta-
mide, apamine, N-[2-[N-(4-chlorocinnamyl)-N-methylaminomethyl]
phenyl]-N-(2-hydroxyethyl)-4 methoxybenzenesulfonamide phos-
phate salt, N-[2-[[[3-(4′-chlorophenyl)-2-propenyl] methylamino]
methyl]phenyl]-N-(2-hydroxyethyl)-4′ methoxybenzenesulfonamide
phosphate salt (KN93), 2 - (4 -morpholinyl) - 8 -phenyl -1(4H) -
benzopyran-4-one hydrochloride (LY 294002), cycloheximide, acryl-
amide and bis-acrylamide were purchased from Sigma Chemical
Company (St. Louis, MO, USA). [32P]Na2HPO4 that was purchased
from the Brazilian Agency of Nuclear Energy (Comissão Nacional de
Energia Nuclear—CNEN), São Paulo, Brazil, was from Amersham Inter-
national (UK). [45Ca]CaCl2 (sp. act. 321 kBq/mg Ca2+), and Optiphase
Hisafe III biodegradable liquid scintillation were purchased from
PerkinElmer (Boston, USA). Anti-p44/42 MAP kinase (anti-ERK1/2),
anti-phospho-p44/42 MAP kinase (anti-phospho ERK1/2), anti p38MAPK
and anti-phospho p38MAPK antibodies were from Cell Signaling Technol-
ogy, Inc. (USA). The anti-VDR (sc-1008) and anti-caveolin-1 (7C8)
(sc-53564) antibodies were obtained from Santa-Cruz. The mouse
anti-NeuN antibody was obtained from Chemicon International (São
Paulo/SP, Brazil). The second antibody goat anti-rabbit IgG coupled to
Alexa Fluor® 594, goat anti-mouse IgG coupled to Alexa Fluor® 430, Pro-
Long® Gold Antifade Reagent and DAPI were from Molecular probes
(Invitrogen). The Immobilon™ Western chemiluminescent HRP sub-
stratewas obtained fromMillipore. All other chemicalswere of analytical
grade.
2.2. Animals
Wistar rats were bred in an animal house and maintained in an
air-conditioned room (about 21 °C) with controlled lighting (12 h/12 h
light/dark cycle). The suckling rats were kept with their mothers until
euthanasia. Pelleted food (Nuvital, Nuvilab CR1, Curitiba, PR, Brazil)
and tap water were available ad libitum. All animals' procedures were
carried out in accordance with ethical recommendations of the Brazilian
Veterinary Medicine Council and the Brazilian College of Animal Experi-
mentation (Protocol CEUA/PP00179).
2.3. Preparation of cerebral cortex slices
Ten day-old male rats were killed by decapitation, and the
cerebral cortex was dissected onto Petri dishes placed on ice and
cut into 400 μm thick slices with a Mcllwain chopper.
2.4. 32P in vitro incorporation
2.4.1. Preincubation and 32P labeling
Slices of cerebral cortex from 10 day-old male rats were initially
preincubated at 30 °C for 20 min in a Krebs–HEPES medium con-
taining 124 mM NaCl, 4 mM KCl, 1.2 mM MgSO4, 25 mM Na-HEPES
(pH 7.4), 12 mM glucose, 1 mM CaCl2, and the following protease
inhibitors: 1 mM benzamidine, 0.1 μM leupeptin, 0.7 μM antipain,
0.7 μM pepstatin and 0.7 μM chymostatin in the presence or absence
of 10 μM H89 [40,43,53–55], 30 μM PD 98059 [43]; 10 μM nifedipine
[43,56,57], 50 μM BAPTA-AM [43,58,59], 0.35 mM cycloheximide
[39,43] or 1 μM Ro 31–8220 [6,60], when indicated. After pre-
incubation, the medium was changed and incubation was carried
out at 30 °C with 100 μl of the basic medium containing 80 μCi of
[32P] orthophosphate with or without addition of H89, BAPTA-AM,
PD98059, Ro 31–8220, nifedipine or cycloheximide in the presence
or absence of 1,25D when indicated. The incubation of tissue slices
with 80 μCi of 32P-orthophosphate supplies the label for mitochondri-
al production of γ32P-ATP used for endogenous kinases. The excess of
radioactive orthophosphate assures the maximal production of
labeled ATP. This experimental approach has been developed by our
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of the in vitro 32P incorporation into cytoskeletal proteins in different
tissues and experimental models [5,39–43,62–64]. The labeling reac-
tionwas normally allowed to proceed for 30 min at 30 °C and stopped
with 1 ml of ice-cold stop buffer (150 mM NaF, 5 mM, EDTA, 5 mM
EGTA, 50 mM Tris–HCl, pH 6.5), and the protease inhibitors described
above. Slices were then washed twice with stop buffer to remove
excess radioactivity and maintained on ice at 4 °C.
2.4.2. Preparation of the high salt-Triton insoluble cytoskeletal fraction
After the labeling reaction, slices were homogenized in 400 μl of
ice-cold high salt buffer containing 5 mM KH2PO4, (pH 7.1), 600 mM
KCl, 10 mM MgCl2, 2 mM EGTA, 1 mM EDTA, 1% Triton X-100 and the
protease inhibitors described above. The homogenate was centrifuged
at 15,800×g for 10 min at 4 °C, in an Eppendorf centrifuge, the superna-
tant discarded and the pellet homogenizedwith the same volume of the
high salt medium. The resuspended homogenate was centrifuged as
described and the supernatant was discarded. The Triton-insoluble
IF-enriched pellet, containing NF subunits, vimentin and GFAP, was dis-
solved in 1% SDS and protein concentration was determined.
2.4.3. Polyacrylamide gel electrophoresis (SDS-PAGE)
The cytoskeletal fraction was prepared as described above. Equal
protein concentrations were loaded onto 10% polyacrylamide gels
and analyzed by SDS-PAGE according to the discontinuous system
of Laemmli [65]. After drying, the gels were exposed to X-ray ﬁlms
(X-Omat XK1) at−70 °C with intensifying screens and ﬁnally the au-
toradiograph was obtained.
2.5. Western blot analysis
In some experiments tissue slices were treated with 1,25D during
5, 10, 15 and/or 30 min, then total tissue extracts were processed to
Western blot analysis. The nitrocellulose membranes were washed
for 10 min in Tris-buffered saline (TBS; 0.5 M NaCl, 20 mM Trizma,
pH 7.5), followed by 2 h incubation in blocking solution (TBS plus
5% defatted dried milk). After incubation, the blot was washed twice
for 5 min with TBS plus 0.05% Tween-20 (T-TBS), and then incubated
overnight at 4 °C in blocking solution containing the following mono-
clonal antibodies designated to study the MAPK cascade: anti-ERK1/2,
anti-phospho ERK1/2, anti p38MAPK and anti-phospho p38MAPK anti-
bodies (diluted 1:2000). The blot was then washed twice for 5 min
with T-TBS and incubated for 2 h in TBS containing peroxidase conju-
gated anti-rabbit IgG 1:1000. The blot was washed twice again for
5 min with T-TBS and twice for 5 min with TBS. The blot was then de-
veloped using Immobilon™Western chemiluminescent HRP substrate.
2.6. Quantitation of Western blot and 32P incorporation into IF proteins
The radioactivity incorporated into cytoskeletal proteins as well as
the immunoblots were quantiﬁed by scanning the ﬁlms with a
Hewlett-Packard Scanjet 6100C scanner and by determining optical
densities for the band corresponding to each protein. Control values
were then normalized to 100% and the percentage changes in the
test samples were calculated. Protein loading was controlled by
Coomassie blue staining the gels.
2.7. 45Ca2+ uptake
Slices of cerebral cortex from 10 day-old male rats were pre-
incubated in Krebs Ringer-bicarbonate (KRb) buffer (122 mM NaCl;
3 mM KCl; 1.2 mM MgSO4; 1.3 mM CaCl2; 0.4 mM KH2PO4; 25 mM
NaHCO3) for 15 min in a Dubnoff metabolic incubator at 37 °C, pH
7.4 and gassed with O2:CO2 (95:5; v/v). After that, the medium was
changed by fresh KRb with 0.1 μCi/ml 45Ca2+ during 60 min. Finally,
1,25D was included in this KRb containing 45Ca2+ and the tissueswere incubated either in the absence (control) or presence of 1,25D
(10−13, 10−12, 10−10, 10−9, and 10−7 M) for 5 min. In some exper-
iments channel blockers or kinase inhibitors were added during
the last 20 min before hormone addition and maintained during all
the incubation period (see ﬁgures). The following drugswere used: ni-
fedipine (10 μM),ﬂunarizine (1 μM), 9-AC (1 μM), BAPTA-AM (50 μM),
dantrolene (50 μM), tolbutamide (100 μM), ouabain (1 μM), H89
(10 μM), theophylline (50 μM), di-BucAMP (500 μM), Ro 31–8220
(20 μM), LY 294002 (10 μM), SB 239063 (10 μM), PD 98059 (10 μM),
and KN93 (10 μM) [43,52,66–69].
Extracellular 45Ca2+ from the cortical slices was thoroughly
washed off in a washing solution containing 127.5 mM NaCl, 4.6 mM
KCl, 1.2 mM MgSO4, 10 mM HEPES, 11 mM glucose, 10 mM LaCl3,
pH 7.3 (30 min in washing solution). The presence of La3+ during
the washing stage was found to be essential to prevent release of the
intracellular 45Ca2+ [70]. After washing, tissue slices were homoge-
nized with 0.5 M NaOH solution, 100 μl aliquots were placed in scin-
tillation ﬂuid and counted in a LKB rack beta liquid scintillation
spectrometer (model LS 6500; Multi-Purpose Scintillation Counter-
Beckman Coulter, Boston, USA) [52,66,69], and 5 μl aliquots were
used for protein quantiﬁcation as described by Lowry and colleagues
[71].2.8. VDR and caveolin-1 immunohistochemistry
Control animals were anesthetized with xylazine (0.1 ml/100 g
body weight, i.m.) and ketamine (0.1 ml/100 g body weight, i.m.)
and perfused with phosphate buffered saline (PBS) with heparin
(50 ml in the 15-day-old rats) followed by 4% paraformaldehyde di-
luted in 0.1 M phosphate buffer (pH 7.4) at 4 °C of the same ﬂow
rate and total amount. The perfusion rate was approximately 100 ml.
After perfusion, the brain was extracted from the skull, weighed, and
placed in the same ﬁxing solution for 72 h. After ﬁxation, the brain
was washed for 1 h in running water, dehydrated in increasing
concentrations of ethanol (70%, 80%, 90%, 95% and absolute ethanol)
and cleared with xylol. Brains were then embedded in paraplastic
resin (Histosec; Merk). Coronal serial sections (3 μm thickness) were
obtained with a microtome and serially collected on glued slides.
Brain slides were deparafﬁnized in toluene, rehydrated in ethanol
and rinsed in tap water. After this step, sections were placed in
0.1 M sodium citrate and citric acid buffer, heated for 20 min in a
350 W microwave oven, allowed to cool for 60 min, and rinsed in
tap water and in PBS three times. Sections then were contoured with
Dakopen and nonspeciﬁc binding sites were blocked with 3%
PBS-BSA for 60 min at room temperature. Thereafter sections were
incubated overnight with rabbit anti-VDR polyclonal antibody,
mouse anti-caveolin-1 (1:500 in 3% PBS-BSA) and/or mouse
anti-NeuN (1:1000 in 3% PBS-BSA) at 4 °C. After thorough rinsing, all
sections were incubated with goat anti-mouse IgG conjugated to
Alexa Fluor® 430 (1:500) and/or goat anti-rabbit IgG conjugated
Alexa Fluor® 594 (1:500) for 45 min at room temperature and
washed with PBS. Nucleus were stained with DAPI (0.25 μg/ml) and
covered with ProLong® Gold Antifade Reagent and coverslips. Nega-
tive controls were performed without primary antibody. Images
were captured with a ﬂuorescence microscope (Olympus, BX-41)
equipped with a digital camera (3.3 Mpixel QCOLOR3C, Qimaging™)
and image acquisition software (Qcapture Pro 5.1, Qimaging™).2.9. Statistical analysis
The results are means±S.E.M. When multiple comparisons were
performed, evaluation was done using one-way ANOVA followed by
a Bonferroni multiple comparison test. Differences were considered
to be signiﬁcant when pb0.05.
Fig. 2. IF phosphorylation induced by 1,25D is independent of protein synthesis. Slices
of cerebral cortex were pre-incubated in the presence or absence of 0.35 mM cyclohex-
imide for 45 min and incubated with 32P-orthophosphate with or without (100 pM)
1,25D during 30 min, as described in Material and methods. The cytoskeletal fraction
was extracted, and analyzed by SDS-PAGE and the radioactivity that was incorporated
into GFAP, vimentin, NF-L and NF-M was measured by determining the optical density
values for the band corresponding to each protein. Data are reported as means±SEM
of 10 animals in each group and expressed as % of control. Statistically signiﬁcant dif-
ferences from controls, as determined by one-way ANOVA followed by a Bonferroni
multiple comparison test are indicated: ⁎Pb0.01.
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3.1. Glial and neuronal IF proteins as a target of membrane-initiated
actions of 1,25D
Slices of cerebral cortex were exposed to different concentrations
of 1,25D and the in vitro phosphorylation of IF-enriched cytoskeletal
fraction was investigated. Results showed that 1,25D exposure for
30 min increased the IF phosphorylation at doses ranging from
10−10 to 10−7 M (Fig. 1). The following experiments were carried
out by using 10−10 M 1,25D. The hormone-induced IF phosphoryla-
tion was totally independent on protein synthesis, as attested by
using 0.35 mM cycloheximide, a potent inhibitor of protein synthe-
sis (Fig. 2), therefore, supporting a nongenomic action of 1,25D
directed to the IF-associated phosphorylating system.
3.2. Involvement of PKA, PKC, PKCaMII and MAPK on 1,25D-induced
IF phosphorylation
The contribution of different protein kinases known to target the
IF proteins [5] was investigated. Interestingly, the effect of 1,25D
(100 pM) was unaffected by the presence of either protein kinase
C (PKC) or MAP kinase kinase (MEK) inhibitors (Ro 31–8220 and
PD 98059, respectively) (Fig. 3A). However, 10 μM H89 (PKA inhib-
itor) or 10 μM KN93 (PKCaMII inhibitor) totally prevented the
1,25D-induced hyperphosphorylation (Fig. 3B). Altogether, these
ﬁndings demonstrate a role for PKA and PKCaMII in the mechanism
of the hormonal action on the homeostasis of the phosphorylating
system targeting the cytoskeleton.
3.3. Involvement of calcium on 1,25D-induced IF phosphorylation
The contribution of calcium signaling to the 1,25D-triggered events
targeting the cytoskeleton was veriﬁed by using 10 μM nifedipineFig. 1. Effect of different concentrations of 1,25D on IF phosphorylation. Slices of cerebral c
doses ranging from 10−12 to 10−7 M. The cytoskeletal fraction was extracted, and analyze
and NF-M was measured by determining the optical density values for the band correspo
and expressed as % of control. Statistically signiﬁcant differences from controls, as determine
⁎Pb0.01; ⁎⁎Pb0.001.(L-VDCC blocker) and 50 μM BAPTA-AM (cell permeable calcium
quelator). Results showed that co-incubation of 1,25D with each one
of these drugs was able to prevent the hormone-stimulated IF-
phosphorylation, evidencing a calcium-dependent mechanism (Fig. 4).
In order to clarify these ﬁndings, the mechanisms involved in
1,25D-mediated Ca2+ entrance were investigated.3.4. Involvement of VDCC and intracellular calcium in the stimulatory
effect of 1,25D on 45Ca2+ uptake
As depicted in Fig. 5, exposure to the secosteroid hormone at 10−10 M
for 5 min was able to increase the 45Ca2+ uptake.
In order to verify the involvement of L- and T-type VDCCs on the
stimulatory effect of 1,25D (10−10 M) on 45Ca2+ uptake, nifedipineortex were incubated with 32P-orthophosphate in the absence or presence of 1,25D at
d by SDS-PAGE and the radioactivity that was incorporated into GFAP, vimentin, NF-L
nding to each protein. Data are reported as mean±SEM of 12 animals in each group
d by one-way ANOVA followed by a Bonferroni multiple comparison test are indicated:
Fig. 3. Involvement of (A) PKC, MAPK, (B) PKA and PKCaMII signaling pathways on 1,25D-induced IF phosphorylation. Slices of cerebral cortex were pre-incubated in the presence
or absence of 1 μM Ro 31–8220 (PKC inhibitor), 30 μM PD 98059 (MEK inhibitor), 10 μM H89 or 10 μM KN93 and incubated with 32P-orthophosphate with or without addition of
drugs and/or 1,25D (100 pM). The cytoskeletal fraction was extracted, and analyzed by SDS-PAGE and the radioactivity that was incorporated into GFAP, vimentin, NF-L and NF-M
was measured by determining the optical density values for the band corresponding to each protein. Data are reported as means±SEM of 10 animals in each group and expressed
as % of control. Statistically signiﬁcant differences as determined by one-way ANOVA followed by a Bonferroni multiple comparison test are indicated: ⁎Pb0.01; ⁎⁎Pb0.01 compared
with control group. #Pb0.05 compared with 1,25D group.
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sults showed that nifedipine (10 μM) prevented the 1,25D action
while ﬂunarizine (1 μM) did not alter the hormone effect, indicating
the participation of L-VDCC in the mechanism of hormone action
(Fig. 6A). Once the participation of L-VDCC on 45Ca2+ uptake in cerebral
cortex was established, we also sought to determine if the intracellular
Ca2+ levels could play a role in regulating the VDCC activity by using
BAPTA-AM to chelate the intracellular Ca2+. Therefore we found that
in the presence of BAPTA-AM the stimulatory effect of 1,25D on the
L-VDCC was abrogated. In addition, the use of dantrolene (50 μM)
allowed us to set the implication of ryanodin receptors in the mecha-
nism of action of 1,25D (Fig. 6B).Fig. 4. Involvement of calcium on 1,25D-induced IF phosphorylation. Slices of cerebral
cortex were pre-incubated in the presence or absence of 10 μM nifedipine or 50 μM
BAPTA-AM for 20 min and incubated with 32P-orthophosphate with or without
(100 pM) 1,25D and/or inhibitors. The cytoskeletal fraction was extracted, and ana-
lyzed by SDS-PAGE and the radioactivity that was incorporated into IFs was measured
by determining the optical density values for the band corresponding to each protein.
Data are reported as means±SEM of 10 animals in each group and expressed as % of
control. Statistically signiﬁcant differences from controls, as determined by one-way
ANOVA followed by a Bonferroni multiple comparison test are indicated: ⁎⁎Pb0.001,
⁎Pb0.01 compared to control group; #Pb0.05, ##Pb0.01 compared to 1,25D group.3.5. Involvement of K+ and Cl− channels in the stimulatory effect of
1,25D on 45Ca2+ uptake
The VDCCs can open in response to changes on resting mem-
brane potential; therefore, in order to investigate if K+ efﬂux or Cl−
inﬂux could lead to 45Ca2+ uptake through VDCCs we used speciﬁc
blockers for ATP-dependent K+ channels (tolbutamide), as well as
for calcium-dependent Cl− channels (9-AC). Results showed that
both tolbutamide (100 μM) and 9-AC (1 μM) prevented the hormone
stimulated 45Ca2+ uptake (Fig. 6C). These data suggest the involve-
ment of K+ and Cl− channels in the mechanism of action of 1,25D in
cerebral cortex.Fig. 5. Dose–response curve of 1,25D on 45Ca2+ uptake on cerebral cortex. Slices of ce-
rebral cortex were pre-incubated for 60 min in the presence of 0.1 μCi/ml of 45Ca2+.
The slices were incubated with or without 1,25D at different concentrations (10−13,
10−12, 10−10, 10−9 and 10−7 M) for 5 min. Data are reported as means±SEM of 8 an-
imals in each group and expressed as % of control. Statistically signiﬁcant differences
from controls, as determined by one-way ANOVA followed by a Bonferroni multiple
comparison test are indicated: ⁎Pb0.05 compared with control group.
Fig. 6. Involvement of (A) voltage-dependent calcium channels (VDCCs) and (B) intracel-
lular Ca2+ levels, as well as (C) K+ and Cl− channels on 45Ca2+ uptake induced by 1,25D
(100 pM) in cerebral cortex of rats. Slices of cerebral cortex were pre-incubated for
60 min in the presence of 0.1 μCi/ml of 45Ca2+. In the last 20 min preincubation 10 μMni-
fedipine (L-VDCC blocker) or 1 μM ﬂunarizine (T-VDCC blocker) (A); 50 μM BAPTA-AM
(intracellular calcium chelator) or 50 μMdantrolene (ryanodine calcium channel blocker)
(B); 100 μM tolbutamide (ATP-dependent potassium channel blocker) or 1 μM 9-AC
(calcium-dependent chloride channel blocker) (C), was added to the incubationmedium.
After that, the slices were treated with or without 1,25D for 5 min (incubation). Data are
reported asmeans±SEM of 8 animals in each group and expressed as % of control. Statis-
tically signiﬁcant differences from controls, as determined by one-way ANOVA followed
by a Bonferroni multiple comparison test are indicated: ⁎⁎Pb0.01 compared with control
group. #Pb0.05, ##Pb0.01 and ###Pb0.001 compared with 1,25D group. @Pb0.05 com-
pared with ﬂunarizine group.
Fig. 7. Involvement of Na+/K+-ATPase on 45Ca2+ uptake in cerebral cortex of rats.
Slices of cerebral cortex were pre-incubated for 60 min in the presence of 0.1 μCi/ml
of 45Ca2+. In the last 20 min preincubation 1 μM ouabain (Na+/K+-ATPase inhibitor)
was added to the incubation medium. After that, the slices were treated with or with-
out 1,25D (100 pM) for 5 min (incubation). Data are reported as means±SEM of 8 an-
imals in each group and expressed as % of control. Statistically signiﬁcant differences
from controls, as determined by one-way ANOVA followed by a Bonferroni multiple
comparison test are indicated: ⁎Pb0.05 and ⁎⁎Pb0.01 compared with control group.
Fig. 8. Involvement of (A) the PKA signaling pathway, (B) Ca2+/calmodulin-dependent
protein kinase, phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), mitogen
activated protein kinase (MAPK), and p38MAPK on 45Ca2+ uptake in cerebral cortex of
rats. Slices of cerebral cortex were pre-incubated for 60 min in the presence of
0.1 μCi/ml of 45Ca2+. In the last 20 min preincubation 10 μM H89 (PKA inhibitor) or
500 μM dibutyryl (cAMP analog), or 100 μM theophylline (phosphodiesterase inhibi-
tor) (A); 10 μM KN93 (PKCamII inhibitor) or 10 μM LY 294002 (PI3K inhibitor), or
20 μM RO 31–8220 (PKC inhibitor), or 10 μM PD 98059 (MAPK inhibitor), or 10 μM
SB 239063 (p38MAPK inhibitor) was added to the incubation medium. After that, the
slices were treated with or without 10−10 M 1,25D for 5 min (incubation). Data are
reported as means±SEM of 8 animals in each group and expressed as % of control. Sta-
tistically signiﬁcant differences from controls, as determined by one-way ANOVA
followed by a Bonferroni multiple comparison test are indicated: ⁎Pb0.05, ⁎⁎Pb0.01
and ⁎⁎⁎Pb0.001 compared with control group. #Pb0.05, ##Pb0.01 and ###Pb0.001
compared with 1,25D group. @Pb0.05 compared with theophylline group.
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on 45Ca2+ uptake
To evaluate the consequences of Na+/K+-ATPase inactivation
on 45Ca2+ uptake we incubated the slices of cerebral cortex in the
presence of ouabain (1 μM), a digitalic glicoside. The pump inhibition
mimicked the 1,25D action on 45Ca2+ uptake (Fig. 7), without induced
cell death evaluated by lactate dehydrogenase (LDH) release (results
not shown).
3.7. Involvement of the PKA signaling pathway in the stimulatory effect
of 1,25D on 45Ca2+ uptake
We also investigated whether the PKA signaling pathway could be
involved in the 1,25D effect on 45Ca2+ uptake. Results demonstrated
that H89 (PKA inhibitor) prevented the 45Ca2+ uptake stimulated by
1,25D. Furthermore, an elevation of cAMP levels in response to 500 μM
di-BucAMP (a cAMP synthetic analog), was able to increase 45Ca2+
uptake. In addition, we did not observe an additional stimulatory effect
when the tissue was co-incubated with the hormone, suggesting
that cAMP on its own participates in the mechanism of action of 1,25Don 45Ca2+ uptake. Also, the effect of 1,25Dwas sustained in the presence
of a phosphodiesterase inhibitor (50 μM theophylline) (Fig. 8A), rein-
forcing the involvement of the cAMP/PKA signaling pathway in the
1,25D-induced 45Ca2+ uptake.
3.8. Involvement of PKCaMII, PI3K, PKC and p38MAPK in the stimulatory
effect of 1,25D on 45Ca2+ uptake
The participation of other protein kinases such as PKCaMII, PI3K,
PKC, and MAPK signaling pathways in 1,25D actions was investigated
by using the speciﬁc inhibitors: (10 μM) KN93, (10 μM) LY294002,
(20 μM) Ro 31–8220, (10 μM) PD 98059 and (10 μM) SB239063, re-
spectively. The outcomes showed that KN93, LY 294002, as well as
Fig. 10. Immunohistochemical double staining shows the immunolocalization of VDR
and caveolin-1 in neurons of cerebral cortex of rats. Immunoﬂuorescence images
show the cell nuclei stained by 40,6-diamidino-2-phenylindole (DAPI) (blue, A), the
subcellular localization of VDR (red, B) and caveolin-1 (green, C). Merged image of A,
B and C illustrating co-localization of both VDR and caveolin-1 proteins (orange, D).
Bars=50 μm.
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while Ro 31–8220 and PD98059 did not change the 1,25D stimulation
on 45Ca2+ uptake (Fig. 8B), suggesting that the ability of 1,25D to
increase 45Ca2+ uptake is associated to activation of PKCaMII, PI3K
and p38MAPK.
3.9. MAPK modulation by 1,25D
To attest the modulation of MAPKs by 1,25D, we investigated the
effect of different times (5, 10, 15 and 30 min) of exposure to the hor-
mone on the activation proﬁle of the enzymes, measuring the total
and phosphorylated levels of ERK1/2 and p38MAPK in cerebral cortex
from immature rats. Results showed that the total levels of ERK1/2
and p38MAPK were unaltered from 1 to 30 min (Fig. 9A and C), while
the phospho-ERK1/2 and phospho-p38MAPK levels signiﬁcantly
increased the ﬁrst 5 min incubation returning to control levels at
30 min exposure to the hormone (Fig. 9B and D).
3.10. VDR/caveolin-1 and VDR/NeuN immunolocalization in cerebral
cortex from young rats
Fig. 10 shows the VDR and caveolin-1 immunolocalization in the
cerebral cortex cells from young rats. The nuclear staining with DAPI
(blue) was demonstrated in Fig. 10A. The analysis revealed a strong
cellular peripheral VDR immunoreactivity (red), but also a weak
staining is shown in the nucleus of neural cells from cerebral cortex
(Fig. 10B). In addition, immunoreactive caveolin-1 (green)was largely
distributed in the cytosol and cell membrane but was largely absent
in the nucleus (Fig. 10C). The colocalization of VDR and caveolin-1 is
depicted in Fig. 10D. Apparently, VDR and caveolin-1 are immuno-
localized in neurons (distinct nucleolus within an ovoid nucleus andFig. 9. Effect of 1,25D on ERK1/2 (A and B) and p38MAPK (C and D) activation in cerebral cortex of rats. Time course activation of ERK1/2 and p38MAPK. After 20 min pre-incubation
tissue slices were incubated for 1, 5, 15 or 30 min with 1,25D (100 pM). Tissue was lysed and the total and phospho levels of ERK1/2 and p38MAPK were measured by Western blot.
Data are reported as means±SEM of 8 animals in each group and expressed as % of control. Statistically signiﬁcant differences as determined by one-way ANOVA followed by a
Tukey–Kramer multiple comparison test are indicated: ⁎Pb0.05 compared with control group.
Fig. 11. Immunohistochemical double staining showing the immunolocalization of
VDR and NeuN in neurons of cerebral cortex of immature rats. Immunoﬂuorescence
images show NeuN staining (green, A), VDR localization (red, B), cell nuclei stained
by DAPI (blue, C), and merged image of A, B and C illustrating immunolocalization of
both VDR and NeuN proteins (orange, D) in neuronal cells. Bars=50 μm.
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by their much smaller size when compared with the neighboring
neurons).
Fig. 11 shows the VDR and NeuN immunolocalization in the cere-
bral cortex cells from 15-day-old rats. Results demonstrated the NeuN
immunoreactivity (green; Fig. 11A) and VDR immunoreactivity (red;
Fig. 11B). The nuclear staining with DAPI (blue) was shown in
Fig. 11C. The outcomes clearly demonstrated that VDR and NeuN
are co-localized, indicating the expression of the VDR in neurons.
4. Discussion
In this study we found that 1,25D induced nongenomic effects in
cerebral cortex of immature rats by modulating Ca2+-mediated signal
transduction, the homeostasis of the cytoskeleton, and neurochemical
parameters. Results showed that the mechanism of hormonal action
involves the participation of protein kinases, intra- and extracellular
Ca2+, as well as the modulation of Cl− and K+ channels.
The evidence that vitamin D plays critical roles in brain physiology
is becoming recognized from ﬁndings linking vitamin D deﬁciency and
the development of neuropsychiatric disorders [72,73]. Vitamin D and
its metabolites were found in human cerebrospinal ﬂuid several years
ago [74], however, the evidence that this hormone plays important
roles in brain was only provided after demonstration of the presence
of the VDR in the central nervous system [75–77] and the involvement
of 1,25D in brain function and development [73,78–80]. Nonetheless,
several questions are still open concerning the 1,25D mechanism of
action in brain. Interestingly, a strong VDR immunostaining in close
proximity to the neuronal cell membrane is clearly visible, which is
colocalized with the plasma membrane protein caveolin-1. It is clas-
sically described that 1,25D regulates gene transcription through
modulation of VDRn [1]. Moreover, initiation of rapid cellular
responses is attributed to a putative plasma membrane-associated
receptor (VDRm) which is present in a caveolae-enriched membrane
fraction [12,16]. In this context MARRS binding protein [17,18] andthe classical VDR [15] have been suggested as possible candidates for
the VDRm. Taking into account these ﬁndings, our data support the
conclusion that the classical VDR, which is normally found in the
nucleus, is also a neuronal plasma membrane-associated receptor, as
demonstrated by the colocalization of VDR and caveolin-1 in cerebral
cortex of immature rats. However, we could not exclude the participa-
tion of MARRS protein in the mechanism of action of 1,25D in cerebral
cortex. Further experiments will be necessary to clarify this point.
Considering the relevance of the cytoskeleton to the physiology of
neural cells, we were interested to assess the molecular mechanisms
underlying the actions of 1,25D on the phosphorylation of GFAP,
vimentin and neuroﬁlament subunits in the cerebral cortex of im-
mature rats. In this context, we have previously demonstrated the
vimentin phosphorylation and polymerization/aggregation as a target
of 1,25D in immature rat testis [5]. Therefore, in the present report we
have demonstrated that 1,25D is upstream of complex membrane-
initiated signaling pathways leading to phosphorylation of the IF pro-
teins from astrocytes (GFAP and vimentin) and neurons (NF-L and
NF-M). However, although the immunohistochemical analyses indi-
cated that VDR is only expressed in neurons, 1,25D induced the phos-
phorylation of GFAP and vimentin, which are proteins expressed in an
astrocyte. The mechanisms underlying such effects probably involve
complex signaling events and interactions between cells. In this con-
text, the neurons may provide additional opportunities for cross-talk
between them and the neighboring cells, such as the astrocytes. Also,
other proteins, such as MARRS, might be participating in the mecha-
nism of action of 1,25D in glial cells, as demonstrated in other tissues
[19,20].
Considering the relevance of Ca2+ overload on the modulation
of the phosphorylating system associated with the cytoskeleton
[5,42,81,82], the blockade of L-VDCC and the intracellular Ca2+ che-
lation totally prevented the effect of 1,25D on IF phosphorylation.
Increased cytosolic Ca2+ levels lead to astrocyte and neuronal IF
phosphorylation by second messenger-dependent protein kinases,
PKA and PKCaMII, supporting the evidence that the neural isoforms
of adenylyl cyclase are activated by calcium [83]. Our results show
that intracellular Ca2+ levels are required for the 1,25D actions, as
demonstrated by treating cerebral cortex slices with BAPTA-AM, an
intracellular Ca2+ chelator, which prevented both hormone-induced
IF phosphorylation and 45Ca2+ uptake. Ca2+ itself is usually the phys-
iological ligand for the ryanodine receptor in the endoplasmic reticu-
lum (ER) [84]. In this context, we evidenced a role for this receptor
on the 1,25D-induced 45Ca2+ uptake by using dantrolene, a ryanodine
receptor blocker. Taken together, our results suggest that the increase
in intracellular Ca2+ levels could activate ryanodine receptors leading
to L-VDCC opening.
Calcium acts as an intracellular messenger controlling cell de-
velopment and function and the involvement of Ca2+-mediated sig-
naling mechanisms in vitamin D effects is currently demonstrated
[5,6,9,52,85]. Also, our results provide evidence that 45Ca2+ uptake
induced by 1,25D is associated with the modulation of L-VDCC but
is unaffected by T-VDCC. These ﬁndings highlight the critical role of
L-VDCC as a mediator of the actions of 1,25D targeting phosphoryla-
tion sites on IF proteins, although we cannot exclude the participation
of other VDCCs in the modulation of intracellular Ca2+ levels.
The Ca2+ inﬂux via VDCCs frequently occurs after plasma mem-
brane depolarization. Thesemechanisms then set off a cascade of events
including activation of protein kinases, which phosphorylate head
domain sites on GFAP and NFL [64]. To clarify the involvement of ionic
ﬂuxes in the mechanism of action of 1,25D, we investigated the par-
ticipation of Cl− and K+ channels and also the Na+/K+-ATPase ac-
tivity in the hormone-induced 45Ca2+ uptake via L-VDCC. Our results
showed that both ouabain (Na+/K+-ATPase inhibitor) and 1,25D in-
creased 45Ca2+ uptake in cerebral cortex slices. It is important to em-
phasize that coincubation with ouabain and 1,25D did not result in an
additive effect, suggesting that they might have a similar mechanism
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effects need further investigation. Taking into account these ﬁndings,
the Na+/K+-ATPase inhibition might lead to intracellular Na+ accu-
mulationwith subsequent L-VDCC opening and consequent 45Ca2+ up-
take. In this context, Nemoto et al. [86] showed that intracellular levels
of Na+ are upstream of Ca2+ inﬂux through L-VDCC in adrenal chro-
mafﬁn cells. Interestingly, the available results presented here clearly
indicate that Cl− and K+ ﬂuxes are important components involved in
the 45Ca2+ uptake activated by 1,25D in cerebral cortex, although the
precise mechanisms underlying such participation are unknown. It is
important to consider that the modulation of neuronal excitability
might be under the control of L-VDCC activity, and also that these chan-
nelsmay act in opposingmanners, depending on the prevalence of cou-
pling to K+ channels. Geier et al. [87] have demonstrated that the
effects of L-VDCCs on membrane voltage occur over a broad potential
range and could involve depolarizing and hyperpolarizing coupling
modes, supporting the cross-talk among 45Ca2+ uptake and K+ and/
or Cl− channels we are evidencing.
In this context, 45Ca2+ uptake through VDCCs could be modulated
by complex mechanisms involving the activities of different protein
kinases [63,88,89] through direct phosphorylation of the channel.
Therefore, the possible involvement of different serine/threonine
kinases such as PKA, PKC, PI3K, PKCaMII and MAPKs in the stimulato-
ry effect of 1,25D-induced 45Ca2+ uptake in cerebral cortex of young
rats was examined. These data suggest that 1,25D-induced 45Ca2+ up-
take is triggered by the inﬂux of this ion through L-VDCC and that PKA
plays an important role in mediating this effect which are in line with
previous studies [6,9,85] and with the evidence that PKC and PKA play
central roles in signal transduction in many cell types [66,88,89].
Accordingly, it has been demonstrated that L-VDCC phosphorylation
by PKA in skeletal muscle resulted in an activation and opening of
the channels [90–92]. Moreover, Vela et al. [93] showed that PKAFig. 12. Schematic representation of 1,25D-induced signaling pathways mediating cerebral
VDR and stimulates a variety of signaling pathways such as PKA, PI3K, PKCaMII and p38. 1
can lead to membrane depolarization and K+, Cl− and VDCC opening. The activated form
Ca2+ into the cells. PKA can also phosphorylate the ryanodine (Ry) receptor and promote the
Ca2+ messenger systems, such as PKCaMII that also could phosphorylate L-VDCC. These eve
IF phosphorylation and consequently lead to cytoskeleton remodeling.and PKC activation leads to depolarization-induced Ca2+ entry
through L-VDCC in GH3 cells. These data reinforce our results demon-
strating the involvement of PKA and PKC in inducing channel opening
and Ca2+ entry leading to IF phosphorylation in cerebral cortex of im-
mature rats. The participation of the cAMP/PKA pathway in the 1,25D
mechanism of actionwas also reinforced by experiments showing that
dibutyryl cAMP as well as theophylline might induce 45Ca2+ uptake.
Otherwise, in contrast with previous studies [6,9], the nongenomic
effects of 1,25D on IF protein phosphorylation and 45Ca2+ inﬂux are
independent on PKC and ERK1/2 activation in developing cerebral cor-
tex. The reasons leading to these ﬁndings remain to be clariﬁed.
Interestingly, the activation of PKCaMII, p38MAPK and PI3K is im-
portant to support the hormonal action of 1,25D on Ca2+ homeostasis.
Recently, Nemoto et al. [86] demonstrated that inhibition of p38MAPK
prevented the 45Ca2+ uptake via VDCCs. Moreover, PI3K activation
was found to be an upstream effector modulating L-type Ca2+ cur-
rents in cardiomyocytes [94]. Also, the phosphorylation of the β sub-
unit of L-VDCC by PKB/Akt, a key effector of the PI3K signaling
pathway, was demonstrated to modulate the gating of these channels
[95,96], further supporting the involvement of PI3K on Ca2+ inﬂux in-
duced by 1,25D as observed by us in immature rat brain.
The early stages of brain development are recognized as the pe-
riods of intense synaptogenesis associated with enhanced neuronal
activity and augmented synaptic plasticity [97]. Interestingly, the
PI3K activation was associated with induction of functional syn-
aptogenesis in the hippocampus [98]. Taken together, this evidence
supports the idea that 1,25D also might induce synapse formation
through PI3K-mediated mechanisms in immature rat brain.
It is now clear that there are interfaces between 1,25D non-
genomic and genomic actions [15,99]. The involvement of p38MAPK
and PI3K in the mechanism of action of 1,25D suggests that probably a
nongenomic-initiated action might lead to late activation of genomiccortex Ca2+ uptake and IF phosphorylation. 1,25D binds to the membrane-associated
,25D might inhibit Na+/K+ ATPase activity with subsequent Na+ accumulation which
of PKA might phosphorylate L-VDCC which could promote the entry of extracellular
Ca2+ release from stocks into endoplasmic reticulum (ER). Intracellular Ca2+ activates
nts might be also involved in the protein synthesis independent astrocyte and neuronal
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scriptional factors and modulate gene transcription [15]. Moreover,
the modulation of MAPK signaling pathways may transduce the
1,25D signal into complex cellular events, such as aromatase expres-
sion [8], that clearly require gene transcription, although not neces-
sarily the participation of VDRn. However, further experiments are
necessary to clarify this point. Recently, Sun et al. [99] demonstrated
that the p38MAPK signaling pathway might regulate VDR mRNA ex-
pression and mediate Ca2+ signaling in preadipocytes. These ﬁndings
present an evident connection among p38MAPK, transcriptional activ-
ity and a variety of possibilities in vitamin D actions.
The participation of PKCaMII modulating Ca2+ channels and IF
phosphorylation demonstrated in this study is in agreement with
previous reports showing that this kinase induces L-VDCC to enter a
gating mode. The authors showed that PKCaM-mediated phosphory-
lation is an essential signaling event triggering L-VDCC facilitation
[100]. The PKCaMII is one of the most prominent protein kinases
present in the brain. The activity of PKCaMII regulates important neu-
ronal functions, such as neurotransmitter synthesis and release,
modulation of ion channel activity, cellular transport, cytoskeleton
phosphorylation, cell morphology and synaptic plasticity. Also, it is
involved in learning and memory, as well as in modulation of gene
expression [40,43,100,101]. It has also been reported that PKCaMII
can phosphorylate and activate the glutamatergic receptor AMPA
resulting in an increase of Ca2+ entry into postsynaptic neurons and
that this event could be related to long-term potentiation [101], and
consequently could be involved with learning and memory. The in-
volvement of different protein kinases in the mechanism of action
of 1,25D in the brain provides an evidence of the hormonal action
and intracellular targets of the hormone during brain development.
In summary, the present study strongly suggests that 1,25D
induces IF phosphorylation and Ca2+ inﬂux by modulating L-VDCC
opening through different kinase activities, as well as by regulating
ionic ﬂuxes in cerebral cortex of young rats. An overview of the pro-
posed mechanism of action for 1,25D in the cerebral cortex of
young rats is depicted in Fig. 12. The modulation of Ca2+ entry into
neural cells by the hormone might participate in the regulation of a
plethora of intracellular processes, such as IF phosphorylation, modu-
lation of neurotransmission, enzymatic activity, protein synthesis and
cell proliferation, as well as synapse formation, reinforcing 1,25D as a
neuroactive substance that could participate in brain pathology and
physiology. Considering that vitamin D deﬁciency can lead to several
types of brain illness, it may be a possible candidate to be used, at
least as an adjuvant, in the pharmacological therapy of neuropsychi-
atric conditions.
Acknowledgements
This work was supported by grants from CAPES, CNPq-Brazil,
PPG-BQA-UFSC, FUNPESQUISA-UFSC and FAPESC. Special thanks to
Biology, Embryology and Genetic Department/Biological Sciences
Centre (BEG-CCB/UFSC) for microscope facilities (FluorBEG) and to
the biologists Chirle Ferreira and Demétrio Gomes for technical assis-
tance. LZ was registered on Pharmacy Postgraduate Program/UFSC-
Brazil and on Ecole Doctorale Normande de Biologie Intégrative,
Santé, Environnement/Université de Caen-France (Project CAPES/
COFECUB 554/07).
References
[1] R. Bouillon, W.H. Okamura, A.W. Norman, Structure–function relationships in
the vitamin D endocrine system, Endocr. Rev. 16 (1995) 200–257.
[2] L.A. Plum, H.F. DeLuca, Vitamin D, disease and therapeutic opportunities, Nat.
Rev. Drug Discov. 9 (2010) 941–955.
[3] R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H.F. Luderer, L.
Lieben, C. Mathieu, M. Demay, Vitamin D and human health: lessons from vita-
min D receptor null mice, Endocr. Rev. 29 (2008) 726–776.[4] E. Garcion, N. Wion-Barbot, C.N. Montero-Menei, F. Berger, D. Wion, New clues
about vitamin D functions in the nervous system, Trends Endocrinol. Metab.
13 (2002) 100–105.
[5] A. Zamoner, P. Pierozan, L.F. Vidal, B.A. Lacerda, N.G. Dos Santos, C.S. Vanzin, R.
Pessoa-Pureur, Vimentin phosphorylation as a target of cell signaling mecha-
nisms induced by 1alpha,25-dihydroxyvitamin D3 in immature rat testes,
Steroids 73 (2008) 1400–1408.
[6] L. Zanatta, A. Zamoner, R. Gonçalves, A.P. Zanatta, H. Bouraïma-Lelong, S.
Carreau, F. Silva, 1α,25-dihydroxyvitamin D(3) signaling pathways on calcium
uptake in 30-day-old rat Sertoli cells, Biochemistry 50 (2011) 10284–10292.
[7] L. Zanatta, A. Zamoner, A.P. Zanatta, H. Bouraïma-Lelong, C. Delalande, B. Bois, S.
Carreau, F.R. Silva, Nongenomic and genomic effects of 1α,25(OH)(2) vitamin
D(3) in rat testis, Life Sci. 89 (2011) 515–523.
[8] L. Zanatta, H. Bouraïma-Lelong, C. Delalande, F.R. Silva, S. Carreau, Regulation of
aromatase expression by 1α,25(OH)2 vitamin D3 in rat testicular cells, Reprod.
Fertil. Dev. 23 (2001) 725–735.
[9] L. Zanatta, A. Zamoner, R. Gonçalves, A.P. Zanatta, H. Bouraïma-Lelong, Bois, S.
Carreau, F.R. Silva, Effect of 1α,25-dihydroxyvitamin D3 in plasma membrane
targets in immature rat testis: ionic channels and gamma-glutamyl tran-
speptidase activity, Arch. Biochem. Biophys. 515 (2011) 46–53.
[10] C. Carlberg, Ligand-mediated conformational changes of the VDR are required
for gene transactivation, J. Steroid Biochem. Mol. Biol. 89–90 (2004) 227–232.
[11] P. Lips, Vitamin D physiology, Prog. Biophys. Mol. Biol. 92 (2006) 4–8.
[12] A.W. Norman, M.T. Mizwicki, P.G. Derek, Steroid-hormone rapid actions, mem-
brane receptors and a conformational ensemble model, Nat. Rev. Drug Discov.
3 (2004) 27–41.
[13] L.P. Zanello, A.W. Norman, Rapid modulation of osteoblast ion channel re-
sponses by 1alpha,25(OH)2-vitamin D3 requires the presence of a functional vi-
tamin D nuclear receptor, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 1589–1594.
[14] J.C. Fleet, Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what
are they and what do they mean? J. Nutr. 134 (2004) 3215–3218.
[15] M.R. Haussler, P.W. Jurutka, M. Mizwieki, A.W. Norman, Vitamin D receptor
(VDR)-mediated actions of 1α,25(OH)2vitamin D3: genomic and non-genomic
mechanisms, Best Pract. Res. Clin. Endocrinol. Metab. 25 (2011) 543–559.
[16] J.A. Huhtakangas, C.J. Olivera, J.E. Bishop, L.P. Zanello, A.W. Norman, The vitamin D re-
ceptor is present in caveolae-enriched plasma membranes and binds 1
alpha,25(OH)2-vitaminD3 in vivo and in vitro, Mol. Endocrinol. 18 (2004) 2660–2671.
[17] I. Nemere, M.C. Dormanen, M.W. Hammond, W.H. Okamura, A.W. Norman,
Identiﬁcation of a speciﬁc binding protein for 1α,25-dihydroxyvitamin D3 in
basal-lateral membranes of chick intestinal epithelium and relationship to
transcaltachia, J. Biol. Chem. 269 (1994) 23750–23756.
[18] I. Nemere, R. Ray, W. McManus, Immunochemical studies on the putative
plasmalemmal receptor for 1,25(OH)2D3 in chick intestine, Am. J. Physiol.
Endocrinol. Metab. 278 (2000) E1104–E1114.
[19] I. Nemere, The 1,25D3-MARRS protein: contribution to steroid stimulated calci-
um uptake in chicks and rats, Steroids 70 (2005) 455–457.
[20] W. Wu, G. Beilhartz, Y. Roy, C.L. Richard, M. Curtin, L. Brown, D. Cadieux, M.
Coppolino, M.C. Farach-Carson, I. Nemere, K.A. Meckling, Nuclear translocation
of the 1,25D3-MARRS (membrane associated rapid response to steroids) recep-
tor protein and NFkappaB in differentiating NB4 leukemia cells, Exp. Cell Res.
(2010) 1101–1108.
[21] C. Annweiler, G. Allali, P. Allain, S. Bridenbaugh, R.A.-M. Schott, W. Kressig, O.
Beauchet, Vitamin D and cognitive performance in adults: a systematic review,
Eur. J. Neurol. 16 (2009) 1083–1089.
[22] W.E. Stumpf, M. Sar, S.A. Clark, H.F. DeLuca, Brain target sites for 1,25-
dihydroxyvitamin D3, Science 215 (1982) 1403–1405.
[23] T.D. Veenstra, K. Prufer, C. Koenigsberger, S.W. Brimijoin, J.P. Grande, R. Kumar,
1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat
embryo, Brain Res. 804 (1998) 193–205.
[24] W.E. Stumpf, L.P. O'Brien, 1,25 (OH)2 vitamin D3 sites of action in the brain: an
autoradiographic study, Histochemistry 87 (1987) 393–406.
[25] K. Prufer, T.D. Veenstra, G.F. Jirikowski, R. Kumar, Distribution of 1,25-
dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal
cord, J. Chem. Neuroanat. 16 (1999) 135–145.
[26] M.K. Sutherland, M.J. Somerville, L.K. Yoong, C. Bergeron, M.R. Haussler, D.R.
McLachlan, Reduction of vitamin D hormone receptor mRNA levels in Alzheimer
as compared to Huntington hippocampus: correlation with calbindin-28k
mRNA levels, Brain Res. Mol. Brain Res. 13 (1992) 239–250.
[27] D.W. Eyles, S. Smith, R. Kinobe, M. Hewisond, J.J. McGrath, Distribution of the
vitamin D receptor and 1a-hydroxylase in human brain, J. Chem. Neuroanat.
29 (2005) 21–30.
[28] J.J. McGrath, F.P. Féron, T.H.J. Burne, A. Mackay-Simc, D.W. Eyles, Vitamin D3 impli-
cations for brain development, J. Steroid Biochem.Mol. Biol. 89–90 (2004) 557–560.
[29] D. Eyles, J. Brown, A. Mackay-Sim, J. McGrath, F. Feron, Vitamin and brain devel-
opment, Neuroscience 118 (2003) 641–653.
[30] S. Ackerley, P. Thornhill, A.J. Grierson, J. Brownlees, B.H. Anderton, P.N. Leigh,
C.E. Shaw, C.C. Miller, Neuroﬁlament heavy chain side arm phosphorylation
regulates axonal transport of neuroﬁlaments, J. Cell Biol. 161 (2003) 489–495.
[31] R. Perrot, R. Berges, A. Bocquet, J. Eyer, Review of the multiple aspects of neu-
roﬁlament functions, and their possible contribution to neurodegeneration,
Mol. Neurobiol. 38 (2008) 27–65.
[32] S.M. de Waegh, V.M.Y. Lee, S.T. Brady, Local modulation of neuroﬁlament phos-
phorylation, axonal caliber, and slow axonal-transport by myelinating
Schwann-cells, Cell 68 (1992) 451–463.
[33] B. Albert, A. Johnson, J. Lewis, M. Raff, K. Roberts, P. Walter, Molecular Biology of
the Cell, Garland Science, ﬁfth ed., Taylor and Francis Group, New York, 2008.
1718 L. Zanatta et al. / Biochimica et Biophysica Acta 1823 (2012) 1708–1719[34] L.F. Eng, R.S. Ghirnikar, Y.L. Lee, Glial ﬁbrillary acidic protein: GFAP-thirty-one
years (1969–2000), Neurochem. Res. 25 (2000) 1439–1451.
[35] S.L. Green, J.M. Westendorf, H. Jaffe, H.C. Pant, L.C. Cork, E.A. Ostrander, F.
Vignaux, J.R. Ferrell, Allelic variants of the canine heavy neuroﬁlament (NFH)
subunit and extensive phosphorylation in dogs with motor neuron disease,
J. Comp. Pathol. 132 (2005) 33–50.
[36] P. Grant, H.C. Pant, Neuroﬁlament protein synthesis and phosphorylation,
J. Neurocytol. 29 (2000) 843–872 (Review).
[37] R.C. Lariviere, J.P. Julien, Functions of intermediate ﬁlaments in neuronal devel-
opment and disease, J. Neurobiol. 58 (2004) 131–148 (Review).
[38] R.A. Nixon, R.K. Sihag, Neuroﬁlament phosphorylation: a new look at regulation
and function, Trends Neurosci. 14 (1991) 501–506 (Review).
[39] A. Zamoner, P.F. Corbelini, C. Funchal, D. Menegaz, F.R. Silva, R. Pessoa-Pureur,
Involvement of calcium-dependent mechanisms in T3-induced phosphorylation
of vimentin of immature rat testis, Life Sci. 77 (2005) 3321–3335.
[40] A. Zamoner, C. Funchal, L. Heimfarth, F.R. Silva, R. Pessoa-Pureur, Short-term ef-
fects of thyroid hormones on cytoskeletal proteins are mediated by GABAergic
mechanisms in slices of cerebral cortex from young rats, Cell. Mol. Neurobiol.
26 (2006) 209–224.
[41] A. Zamoner, C. Funchal, M.C. Jacques-Silva, C. Gottfried, F.R. Barreto Silva, R.
Pessoa-Pureur, Thyroid hormones reorganize the cytoskeleton of glial cells
through Gfap phosphorylation and Rhoa-dependent mechanisms, Cell. Mol.
Neurobiol. 27 (2007) 845–865.
[42] A. Zamoner, L. Heimfarth, R. Pessoa-Pureur, Congenital hypothyroidism is asso-
ciated with intermediate ﬁlament misregulation, glutamate transporters
down-regulation and MAPK activation in developing rat brain, Neurotoxicology
29 (2008) 1092–1099.
[43] A. Zamoner, L. Heimfarth, S. Oliveira Loureiro, C. Royer, F.R. Mena Barreto Silva, R.
Pessoa-Pureur, Nongenomic actions of thyroxine modulate intermediate ﬁlament
phosphorylation in cerebral cortex of rats, Neuroscience 156 (2008) 640–652.
[44] C.P. Turner, R. Miller, C. Smith, L. Brown, K. Blackstone, S.R. Dunham, R. Strehlow,
M. Manfredi, P. Slocum, K. Iverson, M. West, S.L. Ringler, Z.C. Berry, Widespread
neonatal brain damage following calcium channel blockade, Dev. Neurosci. 29
(2007) 213–231.
[45] T.A. Basarsky, V. Parpura, P.G. Haydon, Hippocampal synaptogenesis in cell cul-
ture: developmental time course of synapse formation, calcium inﬂux, and syn-
aptic protein distribution, J. Neurosci. 14 (1994) 6402–6411.
[46] K.P. Scholz, R.J. Miller, Developmental changes in presynaptic calcium channels
coupled to glutamate release in cultured rat hippocampal neurons, J. Neurosci.
15 (1995) 4612–4617.
[47] A.E. West, W.G. Chen, M.B. Dalva, R.E. Dolmetsch, J.M. Kornhauser, A.J. Shaywitz,
M.A. Takasu, X. Tao, M.E. Greenberg, Calcium regulation of neuronal gene ex-
pression, PNAS 98 (2001) 11024–11031.
[48] A. Mantelas, A. Stamatakis, I. Kazanis, H. Philippidis, F. Stylianopoulou, Control of
neuronal nitric oxide synthase and brain-derived neurotrophic factor levels by
GABA-A receptors in the developing rat cortex, Brain Res. Dev. Brain Res. 145
(2003) 185–195.
[49] D. Atlas, O. Wiser, M. Trus, The voltage-gated Ca2+ channel is the Ca2+ sensor of
fast neurotransmitter release, Cell. Mol. Neurobiol. 21 (2001) 717–731.
[50] P.T. Kumar, S. Antony, M.S. Nandhu, J. Sadanandan, G. Naijil, C.S. Paulose,
Vitamin D3 restores altered cholinergic and insulin receptor expression in the
cerebral cortex and muscarinic M3 receptor expression in pancreatic islets of
streptozotocin induced diabetic rats, J. Nutr. Biochem. 22 (2011) 418–425.
[51] L.P. Zanello, A.W. Norman, Stimulation by 1α,25(OH)2-vitamin D3 of whole cell
chloride currents in osteoblastic ROS 17/2. 8 cells: a structure–function study,
J. Biol. Chem. 272 (1997) 22617–22622.
[52] D. Menegaz, A. Barrientos-Duran, A. Kline, F.R.M.B. Silva, A.W. Norman, M.T.
Mizwicki, L.P. Zanello, 1α,25(OH)2-vitamin D3 stimulation of secretion via chlo-
ride channel activation in Sertoli cells, J. Steroid Biochem. Mol. Biol. 11 (2010)
127–134.
[53] C. Funchal, A. Zamoner, A.Q. dos Santos, S.O. Loureiro, M. Wajner, R.
Pessoa-Pureur, Alpha ketoisocaproic acid increases phosphorylation of interme-
diate ﬁlament proteins from rat cerebral cortex by mechanisms involving Ca2+
and cAMP, Neurochem. Res. 30 (2005) 1139–1146.
[54] S. Ciarmatori, D. Kiepe, A. Haarmann, U. Huegel, B. Tönshoff, Signaling mecha-
nisms leading to regulation of proliferation and differentiation of the mesenchy-
mal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I, J. Mol. Endocrinol.
38 (2007) 493–508.
[55] C.A. Barlow, K. Kitiphongspattana, N. Siddiqui, M.W. Roe, B.T. Mossman, K.M.
Lounsbury, Protein kinase A-mediated CREB phosphorylation is an oxidant-
induced survival pathway in alveolar type II cells, Apoptosis 13 (2008) 681–692.
[56] H. El Beheiry, A. Ouanounoua, P.L. Carlen, L-type calcium channel blockade mod-
iﬁes anesthetic actions on aged hippocampal neurons, Neuroscience 147 (2007)
117–126.
[57] S. Kim, S-Y. Nah, H. Rhim, Neuroprotective effects of ginseng saponins against
L-type Ca2+ channel-mediated cell death in rat cortical neurons, Biochem.
Biophys. Res. Commun. 365 (2008) 399–405.
[58] P. Benquet, J. Le Guen, Y. Pichon, F. Tiaho, Differential involvement of Ca(2+)
channels in survival and neurite outgrowth of cultured embryonic cockroach
brain neurons, J. Neurophysiol. 88 (2002) 1475–1490.
[59] J. Kolikova, R. Afzalov, A. Giniatullina, A. Surin, R. Giniatullin, L. Khiroug,
Calcium-dependent trapping of mitochondria near plasma membrane in stimu-
lated astrocytes, Brain Cell Biol. 35 (2006) 75–86.
[60] A. Rosso, M. Pansera, A. Zamoner, L. Zanatta, H. Bouraïma-Lelong, S. Carreau, F.R.
Silva, 1α,25(OH)(2)-vitamin D(3) stimulates rapid plasma membrane calcium in-
ﬂux viaMAPK activation in immature rat Sertoli cells, Biochimie 94 (2012) 146–154.[61] C. Funchal, L.M.W. de Almeida, S.O. Loureiro, L. Vivian, P.L. Pelaez, F.D.B.
Pessutto, A.M. Rosa, M. Wajner, R. Pessoa-Pureur, In vitro phosphorylation of cy-
toskeletal proteins from cerebral cortex of rats, Brain Res. Protoc. 11 (2003)
111–118.
[62] L. Heimfarth, S.O. Loureiro, A. Zamoner, P. de L. Pelaez, C.W. Nogueira, J.B. Rocha,
R. Pessoa-Pureur, Effects of in vivo treatment with diphenyl ditelluride on the
phosphorylation of cytoskeletal proteins in cerebral cortex and hippocampus
of rats, Neurotoxicology 29 (2008) 40–47.
[63] S.O. Loureiro, L. Heimfarth, P. de L. Pelae, C.S. Vanzin, L. Viana, A.T. Wyse, R.
Pessoa-Pureur, Homocysteine activates calcium mediated cell signaling mecha-
nisms targeting the cytoskeleton in rat hippocampus, Int. J. Dev. Neurosci. 26
(2008) 447–455.
[64] P. Pierozan, A. Zamoner, A.K. Soska, B.O. de Lima, K.P. Reis, F. Zamboni, M. Wajne,
R. Pessoa-Pureur, Signaling mechanisms downstream of quinolinic acid
targeting the cytoskeleton of rat striatal neurons and astrocytes, Exp. Neurol.
233 (2012) 391–399.
[65] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of
bacteriophage T4, Nature 277 (1970) 680–685.
[66] A. Zamoner, C. Royer, K.P. Barreto, R. Pessoa-Pureur, F.R. Silva, Ionic involvement
and kinase activity on the mechanism of nongenomic action of thyroid hor-
mones on 45Ca2+ uptake in cerebral cortex from young rats, Neurosci. Res. 57
(2007) 98–103.
[67] A. Katz, Y. Lifshitz, E. Bab-Dinitz, E. Kapri-Pardes, R. Goldshleger, D.M. Tal, S.J.D.
Karlish, Selectivity of digitalis glycosides for isoforms of human Na, K-ATPase,
J. Biol. Chem. 285 (2010) 19582–19592.
[68] D. Menegaz, A. Rosso, C. Royer, L.D. Leite, A.R.S. Santos, F.R.M.B. Silva, Role of
1,25(OH)2 vitamin D3 on alpha-[1-14C]MeAIB accumulation in immature rat tes-
tis, Steroids 74 (2009) 264–269.
[69] D. Menegaz, C. Royer, A. Rosso, A.Z.P. De Souza, A.R.S. Santos, F.R.M.B. Silva,
Rapid stimulatory effect of thyroxine on plasma membrane transport systems:
calcium uptake and neutral amino acid accumulation in immature rat testis,
Int. J. Biochem. Cell Biol. 42 (2010) 1046–1051.
[70] S. Batra, C. Sjögren, Effect of estrogen treatment on calcium uptake by the rat
uterine smooth muscle, Life Sci. 32 (1983) 315–319.
[71] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein measurement with
the Folin phenol reagent, J. Biol. Chem. 193 (1951) 265–275.
[72] A. Ubbenhorst, S. Striebich, F. Lang, U.E. Lang, Exploring the relationship be-
tween vitamin D and basic personality traits, Psychopharmacology (Berl.) 215
(2011) 733–737.
[73] Y. Miyake, K. Tanaka, W. Fukushima, S. Sasaki, C. Kiyohara, Y. Tsuboi, T. Yamada,
T. Oeda, T. Miki, N. Kawamura, N. Sakae, H. Fukuyama, Y. Hirota, M. Nagai,
Fukuoka Kinki Parkinson's Disease Study Group, Lack of association of dairy
food, calcium, and vitamin D intake with the risk of Parkinson's disease: a
case–control study in Japan, Parkinsonism Relat. Disord. 17 (2011) 112–116.
[74] S. Balabanova, H.P. Richter, G. Antoniadis, J. Homoki, N. Kremmer, J. Hanle, W.M.
Teller, 25-HydroxyvitaminD, 24,25-dihydroxyvitaminD and 1,25-dihydroxyvitamin
D in human cerebrospinal ﬂuid, Klin. Wochenschr. 62 (1984) 1086–1090.
[75] H.J. Bidmon, W.E. Stumpf, Distribution of target cells for 1,25-dihydroxyvitamin
D3 in the brain of the yellow bellied turtle Trachemys scripta, Brain Res. 640
(1994) 277–285.
[76] H.J. Bidmon, W.E. Stumpf, Vitamin D target systems in the brain of the green
lizard Anolis carolinensis, Anat. Embryol. (Berl.) 193 (1996) 145–160.
[77] M. Musiol, W.E. Stumpf, H.J. Bidmon, C. Heiss, A. Mayerhofer, A. Bartke, Vitamin
D nuclear binding to neurons of the septal, substriatal and amygdaloid area
in the Siberian hamster (Phodopus sungorus) brain, Neuroscience 48 (1992)
841–848.
[78] L.D. Brewer, N.M. Porter, D.S. Kerr, P.W. Landﬁeld, O. Thibault, Chronic
1alpha,25-(OH)2 vitamin D3 treatment reduces Ca2+-mediated hippocampal
biomarkers of aging, Cell Calcium 40 (2006) 277–286.
[79] D.W. Eyles, F. Feron, X. Cui, J.P. Kesby, L.H. Harms, P. Ko, J.J. McGrath, T.H. Burne,
Developmental vitamin D deﬁciency causes abnormal brain development,
Psychoneuroendocrinology 34 (2009) S247–S257.
[80] F. Marini, E. Bartoccini, G. Cascianelli, V. Voccoli, M.G. Baviglia, M.V. Magni, M.
Garcia-Gil, E. Albi, Effect of 1alpha,25-dihydroxyvitamin D3 in embryonic hippo-
campal cells, Hippocampus 20 (2010) 696–705.
[81] S.O. Loureiro, P. de Lima Pelaez, L. Heimfarth, D.O. Souza, M. Wajner, R.
Pessoa-Pureur, Propionic and methylmalonic acids increase cAMP levels in slices
of cerebral cortex of young rats via adrenergic and glutamatergic mechanisms,
Biochim. Biophys. Acta 1740 (2005) 460–466.
[82] S.O. Loureiro, L. Heimfarth, B.A. Lacerda, L.F. Vidal, A. Soska, N.G. dos Santos, A.T.
de Souza Wyse, R. Pessoa-Pureur, Homocysteine induces hypophosphorylation
of intermediate ﬁlaments and reorganization of actin cytoskeleton in C6 glioma
cells, Cell. Mol. Neurobiol. 30 (2010) 557–568.
[83] D. Steiner, D. Saya, E. Schallmach, W.F. Simonds, Z. Vogel, Adenylyl cyclase
type-VIII activity is regulated by G (betagamma) subunits, Cell. Signal. 18
(2006) 62–68.
[84] G.S. Bird, J.W. Putney Jr., Calcium, In: in: G.J. Siegel, R.W. Albers, S.T. Brady, D.L.
Price (Eds.), Basic Neurochemistry: Molecular, Cellular and Medical Aspects,
Elsevier Academic Press, San Diego, 2006, pp. 379–390.
[85] A.R. de Boland, A. Norman, Evidence for involvement of protein kinase C and
cyclic adenosine 3′,5′ monophosphate-dependent protein kinase in the 1,25-
dihydroxy-vitamin D3-mediated rapid stimulation of intestinal calcium trans-
port, (transcaltachia), Endocrinology 127 (1990) 39–45.
[86] T. Nemoto, S. Miyazaki, T. Kanai, T. Maruta, S. Satoh, N. Yoshikawa, T. Yanagita, A.
Wada, Nav1.7-Ca2+ inﬂux-induced increased phosphorylations of extracellular
signal-regulated kinase (ERK) and p38 attenuate tau phosphorylation via
1719L. Zanatta et al. / Biochimica et Biophysica Acta 1823 (2012) 1708–1719glycogen synthase kinase-3 beta: priming of Nav1.7 gating by ERK and p38, Eur.
J. Pharmacol. 640 (2010) 20–28.
[87] P. Geier, M. Lagler, S. Boehm, H. Kubista, Dynamic interplay of excitatory and in-
hibitory coupling modes of neuronal L-type calcium channels, Am. J. Physiol. Cell
Physiol. 300 (2011) C937–C949.
[88] T. Gao, T.S. Puri, B.L. Gerhardstein, A.J. Chien, R.D. Green, M.M. Hosey, Identiﬁca-
tion and subcellular localization of the subunits of L-type calcium channels and
adenylyl cyclase in cardiac myocytes, J. Biol. Chem. 272 (1997) 19401–19407.
[89] J.H. Ko, W.S. Park, Y.E. Earm, The protein kinase inhibitor, staurosporine, inhibits
L-type Ca2+ current in rabbit atrial myocytes, Biochem. Biophys. Res. Commun.
329 (2005) 531–537.
[90] C.F. Chang, L.M. Gutierrez, C. Mundina-Weilenmann, M.M. Hosey,
Dihydropyridine-sensitive calcium channels from skeletal muscle. II. Functional
effects of differential phosphorylation of channel subunit, J. Biol. Chem. 266
(1991) 16395–16400.
[91] O. Delbono, M. Renganathan, M.L. Messi, Regulation of mouse skeletal muscle
L-type Ca2+ channel by activation of the insulin-like growth factor-1 receptor,
J. Neurosci. 17 (1997) 6918–6928.
[92] B.D. Johnson, T. Scheuer, W.A. Catterall, Convergent regulation of skeletal mus-
cle Ca2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent
protein kinase, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4191–4196.
[93] J. Vela, M.I. Pérez-Millán, D. Becu-Villalobos, G. Díaz-Torga, Different kinases
regulate activation of voltage-dependent calcium channels by depolarization
in GH3 cells, Am. J. Physiol. Cell Physiol. 293 (2007) C951–C959.[94] Z. Alvin, G.G. Laurence, B.R. Coleman, A. Zhao,M. Hajj-Moussa, G.E. Haddad, Regula-
tion of L-type inward calcium channel activity by captopril and angiotensin II via the
phosphatidyl inositol 3-kinase pathway in cardiomyocytes from volume-overload
hypertrophied rat hearts, Can. J. Physiol. Pharmacol. 89 (2011) 206–215.
[95] A.C. Dolphin, G protein modulation of voltage-gated calcium channels,
Pharmacol. Rev. 55 (2003) 607–627.
[96] P. Viard, A.J. Butcher, G. Halet, A. Davies, B. Nürnberg, F. Heblich, A.C. Dolphin,
PI3K promotes voltage-dependent calcium channel trafﬁcking to the plasma
membrane, Nat. Neurosci. 7 (2004) 939–946.
[97] B. Sutor, H.J. Luhmann, Development of excitatory and inhibitory postsynaptic
potentials in the rat neocortex, Perspect. Dev. Neurobiol. 2 (1995) 409–419.
[98] G. Cuesto, L. Enriquez-Barreto, C. Caramés, M. Cantarero, X. Gasull, C. Sandi, A.
Ferrús, A. Acebes, M. Morales, Phosphoinositide-3-kinase activation controls
synaptogenesis and spinogenesis in hippocampal neurons, J. Neurosci. 31
(2011) 2721–2733.
[99] C. Sun, R. Qi, L. Wang, J. Yan, Y. Wang, p38 MAPK regulates calcium signal-
mediated lipid accumulation through changing VDR expression in primary pre-
adipocytes of mice, Mol. Biol. Rep. 39 (2012) 3179–3184.
[100] I. Dzhura, Y. Wu, R.J. Colbran, J.R. Balser, M.E. Anderson, Calmodulin kinase de-
termines calcium-dependent facilitation of L-type calcium channels, Nat. Cell
Biol. 2 (2000) 173–177.
[101] E. Miyamoto, Molecular mechanism of neuronal plasticity: induction and main-
tenance of long-term potentiation in the hippocampus, J. Pharmacol. Sci. 100
(2006) 433–442.
